First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

被引：16

作者：

De Bono, Johann S.

Tan, David Shao Peng

Caldwell, Reece

Terbuch, Angelika

Goh, Boon C.

Heong, Valerie

Haris, Noor Md

Bashir, Saira

Hong, David S.

Meric-Bernstam, Funda

Bordia, Sonal

Liu, Li

Wilkinson, Gary

Hreiki, Joseph

Wengner, Antje

Fischer, Kerstin

Boix, Oliver

Lagkadinou, Eleni

Plummer, Elizabeth

Yap, Timothy A.

机构：

[1] Royal Marsden NHS Fdn Trust, London, England

[2] Inst Canc Res, London, England

[3] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore

[4] Royal Marsden NHS Trust, London, England

[5] Royal Marsden Hosp, Sutton, Surrey, England

[6] Inst Canc Res, Sutton, Surrey, England

[7] Natl Univ Canc Inst, Singapore, Singapore

[8] Royal Womens Hosp, Melbourne, Vic, Australia

[9] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Bayer, Brooklyn, NY USA

[12] Bayer HealthCare Pharmaceut, Whippany, NJ USA

[13] Bayer AG, Berlin, Germany

[14] Bayer, New York, NY USA

[15] Bayer Pharma AG, Wuppertal, Germany

[16] Bayer Pharma, Berlin, Germany

[17] Freeman Hosp Newcastle, Newcastle, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.3007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3007

引用

页数：2